RxDoctor Payments Data

Hannah Cummings, NP

Primary Care · Suwanee, GANPI 1194219394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 533 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,658in general payments, 2019–2025

Across 533 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$823
  • Amgen$643
  • Tris Pharma Inc$455
  • Lilly USA, LLC$403
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$8,41397%
  • Education$2453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,658 in reported general payments places this provider in the 95th percentile of 235 primary care providers in Georgia.

See all primary care providers in Georgia

Medicare billing

Part B allowed, 2024
$46,965
Medicare patients
130
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide17$21,533
WegovySemaglutide11$17,253
SynthroidLevothyroxine Sodium25$2,292
Atorvastatin Calcium135$1,314
Temazepam13$1,076
Levothyroxine Sodium101$939
Bupropion XlBupropion Hcl21$869
Pregabalin28$868
Rosuvastatin Calcium68$748
Pantoprazole Sodium38$576
Olmesartan Medoxomil73$569
ValacyclovirValacyclovir Hcl16$519
Valsartan11$455
Buspirone Hcl25$447
Fluoxetine Hcl12$427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Wegovy$1,339$38,78628 claims
AbbVieSynthroid$1,217$2,29225 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$43$1,286119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 primary care providers in Georgia.

Other primary care in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →